Your browser doesn't support javascript.
loading
Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Zekri, Jamal; Nawaz, Azhar; Rasool, Haleem; Ahmad, Imran; Abdel Rahman, Hossam; Dada, Reyad; Abdelghany, Ehab Mosaad; Farag, Kamel; Ibrahim, Refaei Belal; Deibas, Mohamed Youssef; Kamel, Mohamed Kamal; Allithy, Ahmed.
Afiliación
  • Zekri J; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Nawaz A; College of Medicine, Al-Faisal University, Riyadh, Saudi Arabia.
  • Rasool H; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Ahmad I; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Abdel Rahman H; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Dada R; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Abdelghany EM; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Farag K; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Ibrahim RB; National Cancer Institute, Cairo, Egypt.
  • Deibas MY; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
  • Kamel MK; Department of Medical Oncology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
  • Allithy A; King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
J Oncol Pharm Pract ; 28(8): 1681-1686, 2022 Dec.
Article en En | MEDLINE | ID: mdl-34342555
BACKGROUND: Febrile neutropenia (FN) is a life-threatening complication of Docetaxel-based chemotherapy regimens (DBRs). Prophylactic granulocyte-colony stimulating factor (G-CSF) can reduce the risk of FN. This study investigated the effect of G-CSF on FN in patients receiving DBRs for breast cancer. METHODS: Patients treated between 2015 and 2017 were identified from the hospital's pharmacy database and their medical records were examined retrospectively. Data from patients' first four cycles of DBR were collected. FN rate, FN associated length of hospital stay (FN-LOS), and chemotherapy dose modification/delay due to FN were compared between patients who did (G-CSF group) or did not (non-GCSF group) receive prophylactic G-CSF. RESULTS: Of the 276 included patients, 83.3% received a DBR as adjuvant or neoadjuvant therapy, and 50% received docetaxel as combination therapy. Prophylactic G-CSF was administered with the first cycle of a DBR in 69.9% of patients who were significantly less likely to experience FN compared to the non-G-CSF group (6.2% vs. 15.7%; odds ratio: 0.36 [95% CI: 0.16-0.82]; p = 0.020). Collectively and after the 4 DBR treatment cycles, FN rate (4.8 vs. 8.5; odds ratio: 0.54 [95% CI: 0.30-0.97]; p = 0.043) and the mean FN-LOS (3.55 vs. 5.28 days; t = -2.22; p = 0.037) were reduced in the G-CSF group. There was no difference in DBR dose delay/reduction between both groups in cycles 2-4. CONCLUSION: In patients receiving DBRs for breast cancer, prophylactic G-CSF significantly reduced both the rate of FN and duration of hospitalization for FN.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neutropenia Febril Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2022 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neutropenia Febril Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2022 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido